Shares of Halozyme Therapeutics, Inc. (HALO) were up 5% on Jan. 8 after the company raised its guidance for 2025. The stock gained another 1.8% in after-hours trading. HALO also maintained its full-year 2024 financial guidanceThe company also announced that it has entered into a new $250 million accelerated share repurchase program under the previously announced $750 million share repurchase program.HALO’s top line comprises product sales, royalty payments from Roche (RHHBY) for Phesgo and J&J (JNJ) for sub ...

财务指引 - 公司重申2024年财务指引，预计总营收为9.7亿至10.2亿美元，调整后EBITDA为5.95亿至6.25亿美元[1][4] - 公司上调2025年财务指引，预计总营收为11.5亿至12.25亿美元，同比增长16%至23%，调整后EBITDA为7.55亿至8.05亿美元，同比增长24%至32%[1][6] - 公司预计2024年净利润为4.19亿至4.43亿美元，GAAP稀释每股收益为3.22至3.40美元[4][21] - 公司预计2024年非GAAP稀释每股收益为4.00至4.20美元[4][21] - 公司预计2024年EBITDA为5.95亿至6.25亿美元，调整后EBITDA与EBITDA一致[4][21] 特许权收入 - 2025年特许权收入预计为7.25亿至7.5亿美元，同比增长30%至35%[6][8] - 公司预计2025年特许权收入增长主要受VYVGART Hytrulo、Darzalex SC和Phesgo的强劲增长驱动[3][6] 股票回购计划 - 公司宣布新的2.5亿美元加速股票回购计划[1][2] 新产品收入贡献 - 公司预计2025年新产品Ocrevus Zunovo、Tecentriq Hybreza和Opdivo Qvantig将在2026年及以后显著贡献收入[3] 调整与税收 - 调整涉及税收对账项目、股票薪酬的超额收益或税收不足以及其他离散项目的季度影响[22] - 调整考虑了2028年到期的可转换优先票据在GAAP和非GAAP基础上的稀释效应差异[22] 每股收益 - 2025年非GAAP稀释每股收益预计为4.95至5.35美元，同比增长21%至30%[1][6]

Reports Preliminary 2024 Unaudited Estimated Ranges Consistent with Previous Financial Guidance Raises 2025 Financial Guidance Ranges for Total Revenue to $1,150 - $1,225 million, Representing YoY Growth of 16% - 23%, Adjusted EBITDA of $755 - $805 million, Representing YoY Growth of 24% - 32%, and non-GAAP Diluted EPS of $4.95 - $5.35, Representing YoY Growth of 21% - 30%1,2Announces New $250 million Accelerated Share RepurchaseConference Call Scheduled Today at 5:30am PT/8:30am ETSAN DIEGO, Jan. 8, 2025 / ...

SAN DIEGO, Jan. 6, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday, January 8, 2025, at 5:30 a.m. PT / 8:30 a.m. ET.On the call, Dr. Helen Torley, President and Chief Executive Officer, and Nicole LaBrosse, Chief Financial Officer, will provide preliminary unaudited full year 2024 results and updated 2025 and multi-year financial guidance.Pre-registration of the live call can be accessed via link here: https:/ ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts ...

SAN DIEGO, Dec. 30, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Takeda received regulatory approval for HYQVIA® [Immune Globulin Infusion 10% (Human) with Halozyme's Recombinant Human Hyaluronidase] by the Japanese Ministry of Health, Labour and Welfare (MHLW) for patients with agammaglobulinemia or hypogammaglobulinemia, disorders characterized by very low or absent levels of antibodies and an increased risk of serious recurring infection caused by primar ...

SAN DIEGO, Dec. 30, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx's VYVDURA (efgartigimod alfa and hyaluronidase-qvfc), which is co-formulated with Halozyme's ENHANZE® drug delivery technology, was granted regulatory approval by Japan's Ministry of Health, Labour and Welfare (MHLW) for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). VYVDURA was approved for CIDP as a once weekly 30-to-90 second subcutaneous injection, which can b ...

Opdivo Qvantig represents the first and only subcutaneously administered PD-1 inhibitor Opdivo Qvantig demonstrated consistent efficacy and showed a comparable safety profile to IV Opdivo in the Phase 3 CheckMate-67T trialSAN DIEGO, Dec. 30, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Bristol Myers Squibb received U.S. Food and Drug Administration (FDA) approval for Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) co-formulated with Halozyme's ENHANZE® d ...

分组1: 公司增长潜力 - 公司Halozyme Therapeutics的EPS预计今年增长46.3%，远超行业平均的23.5% [6] - 公司过去3-5年的年化现金流增长率为48.7%，远高于行业平均的2.9% [7] - 公司当前年度收益预期在过去一个月内上调了1.2% [14] 分组2: 增长股票特征 - 增长股票通常具有高于平均水平的财务增长，能够吸引市场关注并产生超额回报 [4] - 研究表明，具有最佳增长特征的股票持续跑赢市场，尤其是那些同时具备A或B级增长评分和Zacks Rank 1或2评级的股票 [5] - 现金流增长对增长型公司尤为重要，因为它使公司能够在不依赖外部资金的情况下扩展业务 [3] 分组3: 公司评级与投资建议 - Halozyme Therapeutics获得了B级增长评分，并因其积极的收益预期修正而获得Zacks Rank 2评级 [19] - 公司被认为是增长投资者的潜在优异表现者，并且是Zacks系统推荐的股票之一 [10][16] 分组4: 行业对比 - Halozyme Therapeutics的年度现金流增长率为19.7%，远高于行业平均的-2.6% [18] - 公司的EPS增长率和现金流增长率均显著高于行业平均水平，显示出其在行业中的竞争优势 [6][7]

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Halozyme Therapeutics (HALO) and Amicus Therapeutics (FOLD) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank favors s ...